Title
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial
Phase
Phase 3Lead Sponsor
University of AmsterdamStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Solid TumorsIntervention/Treatment
urea palonosetron metoclopramide ...Study Participants
249In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy (MEC).
Inclusion Criteria: Patient has been diagnosed with histologically or cytologically confirmed solid cancer Starting with first cycle of chemotherapy of moderate emetogenic risk, which does not include a combination of anthracycline plus cyclophosphamide Age ≥ 18 WHO ≤ 1 Patient is able to understand and speak Dutch Exclusion Criteria: Patient with nausea and/or vomiting in 48 hours before start of chemotherapy treatment Patient submitted to concomitant radiotherapy or submitted to radiotherapy 15 days before start of chemotherapy or planned to receive radiotherapy during 8 days after administration of chemotherapy Patient with concomitant severe comorbidy, such as: o Intestinal obstruction o Active peptic ulcer o Hypercalcemia o Uncontrolled diabetes mellitus o Pheochromocytoma o Tardive dyskinesia o Epilepsia o Active infective diseases o Brain - or leptomeningeal metastases o Psychiatrical disorders o Parkinsonism Current use of corticosteroids (similar to prednisone ≥ 10 milligrams per day) Current alcohol abuse Pregnancy